Intact Genomics (IG®) will participate in the 2025 Stanford Drug Discovery Symposium, which will take place April 28–29 at Stanford University. The prestigious event brings together leading researchers, biotech innovators, and pharmaceutical executives to discuss groundbreaking advancements in drug discovery and development.

Representatives from Intact Genomics, a growing leader in molecular biology reagents and point-of-care diagnostics, are engaging with top scientists and industry partners during the two-day symposium. The company is showcasing its latest innovations, including its newly developed and launched Direct Capture of Large Intact Genomic DNA technologies (DCLD™ technologies), RPA kits, PEmax Enzyme, and other molecular diagnostic and gene-editing solutions designed to accelerate gene function studies and drug discovery workflows.

“Our mission is to empower researchers with the tools they need to drive scientific breakthroughs,” said Dr. Charles Wu, CEO of Intact Genomics. “Being part of the Stanford Drug Discovery Symposium is a tremendous opportunity for us to connect with the global scientific community and contribute to conversations that shape the future of medicine.”

This year’s symposium features keynote speeches by Nobel laureates, presentations on AI in drug discovery, advances in targeted therapeutics, and panels on the future of personalized medicine. Intact Genomics’ presence highlights its commitment to supporting innovation and collaboration across the life sciences industry.

In honor of Women’s History Month, Intact Genomics participated in a marketplace vendor show at Washington University in St. Louis on March 18, 2025. Washington University in St. Louis is one of the most prominent research universities in the US. Since 2014, Intact Genomics has provided high-quality molecular biology-related products and services for researchers at WUSTL. These resources help researchers to explore human genes and functional genomics, to better understand the causes of disease, and to advance therapeutics and diagnostic sciences.

Rosa Ye, COO of Intact Genomics, and Jennifer Gormley, VP of Business Development, attended the event and took interviews.

Women play a crucial role at Intact Genomics, contributing significantly across various departments, from operations and marketing to research and development. Their leadership, expertise, and dedication drive innovation, enhance customer engagement, strengthen our company’s growth, and help shape the future of life sciences.

In February, we welcomed our local news station for an insightful discussion on the recent NIH funding cuts and their potential impact on the scientific community.

Despite uncertainties, Intact Genomics remains committed to supporting research and pushing innovation forward. Our team is dedicated to making a difference and we are grateful for the opportunity to share our perspective.

We are thrilled to announce that Intact Genomics has been selected by the prestigious NIH SEED Company Showcase Program to participate in the Redefining Early Stage Investments (RESI) Conference 2025.

The Redefining Early Stage Investments (RESI) Conference 2025 is an important event for the life sciences sector, focusing on connecting early-stage life science companies with investors and strategic partners. The conference will take place on January 14, 2025, at the San Francisco Marriott Marquis, featuring in-person networking opportunities, followed by virtual partnering sessions from January 15-16. This event is part of the broader J.P. Morgan (JPM) Healthcare Week 2025. This week-long event is one of the largest gatherings of global healthcare leaders, including executives, investors, and innovators.

This recognition highlights Intact Genomics’ innovative work in molecular biology, drug discovery and diagnostics. The NIH SEED program supports companies whose track records demonstrate high-potential, and we are honored to be among those chosen to present our breakthroughs to a global audience of investors, industry leaders, and key stakeholders.

At the RESI Conference, Jennifer Gormley, VP of Business Development, and Dr. Chengcang Charles Wu, CEO of Intact Genomics will pitch IG®’s unique technologies including Direct Capture of Large DNA Fragments and Fungal Artificial Chromosome (FAC). We are proud to represent Intact Genomics on this important stage and look forward to engaging with potential investors and building strategic partnerships to accelerate our mission of advancing cutting-edge solutions that address critical challenges in healthcare and life sciences.

Stay tuned for updates as we gear up for this exciting event!

November 25, 2024 – Intact Genomics (IG®), a leading molecular biology reagent company, is proud to announce the launch of three new cutting-edge products tailored to enhance Recombinase Polymerase Amplification (RPA) technology. These new additions mark a significant step forward in delivering reliable, efficient, and user-friendly solutions for rapid nucleic acid detection. All IG RPA-related kits and enzymes can be in custom formats, including high concentrations, and they support lyophilization applications.

The three products include:

1. ig® Recombinase Polymerase Amplification (RPA) Kit v2
   Designed for superior accuracy, this kit offers enhanced performance in detecting low-abundance DNA and RNA sequences, ensuring reliable results even in challenging conditions.
2. FastAmp® qRPA SYBR kit
   FastAmp® qRPA SYBR Kit is a powerful tool to screen primer conditions for the lowest possible Non-template control (NTC) background.
3. FastAmp® Plant Direct RPA kit
   FastAmp® Plant Direct RPA kit offers a fast, robust method for amplifying DNA fragments from plant tissues at a single and constant temperature (37°C).

“These products exemplify our commitment to innovation and meeting the needs of our customers, ” said Charles Wu, CEO of Intact Genomics. “RPA technology has become a cornerstone in molecular diagnostics and genome research. With investment in new equipment and improvement in productivity, we also can offer more affordable high-quality products now. These new offerings aim to empower scientists with the tools they need for faster and more reliable results at lower costs.”

The launch of these products aligns with Intact Genomics’ mission to advance molecular biology solutions and underscores its role as a trusted partner in the scientific community. For more information about these products, or contact IG team at [email protected].

[St. Louis, September 3, 2024] – Intact Genomics, a pioneering molecular biology reagent company that provides first-class products and services for DNA/RNA isothermal amplification for disease diagnostics, simplified molecular cloning and transformation, gene-editing, and large DNA fragment cloning, is pleased to announce that BioQuote has been appointed as its exclusive distributor in the United Kingdom.

Established in 1988, BioQuote Limited is a fast-growing biotech company that is focused on the supply of innovative, quality-branded bioproducts to the bioscience industry. BioQuote will now exclusively distribute IG’s range of high-quality molecular biology reagents across the UK. The partnership combines Intact Genomics’ superior product portfolio with BioQuote’s extensive distribution network and market expertise.

“We are delighted to partner with BioQuote, whose commitment to excellence aligns perfectly with our own values,” said Rosa Ye, COO at Intact Genomics. “This collaboration will enhance our ability to serve researchers and laboratories in the UK, ensuring they have access to the advanced reagents they need to drive scientific discovery and innovation.”

This strategic partnership marks a new milestone in Intact Genomics’ ongoing efforts to expand its international presence and provide cutting-edge reagents and expert solutions to the life science research community in the United Kingdom.

Our CEO, Dr. Chengcang Charles Wu, attended the 16th annual Next Generation Dx Summit (https://www.nextgenerationdx.com) at the Capital Hilton in Washington D.C. where he had a post presentation and networked with other professionals and researchers to discuss important topics surrounding diagnostic advancements. Intact Genomics is a key player and contributor to novel diagnostic technology development, and we reviewed the innovative products and technologies this event featured.  

At the SIVB World Congress, Intact Genomics proudly showcased our new and existing products to hundreds of event attendees from around the world. Our Sales Director, Matthew Jones, Business Development Director, Jennifer Gormley, and CEO, Dr. Chengcang Charles Wu, were able to connect with other biotechnology researchers and professionals to discuss collaboration opportunities. We pride ourselves in our ability to innovate and grow as in vitro biology research continues to evolve. Intact Genomics provides a range of superior quality products and services including Recombinase Polymerase Amplification (RPA) optimization enzymes, custom competent cells, DirectPlate® competent cells, and the Quick10™ cloning kit. 

Intact Genomics (IG®) scientists and collaborators published 3 papers in peer-reviewed journals recently. For further details, click the links below or contact us for inquiries.

“Activation of cryptic biosynthetic gene clusters by fungal artificial chromosomes to produce novel secondary metabolites”. AIMS Microbiol, 2023; 9(4): 757–779. Published online 2023 Dec 18
“The Identification and Heterologous Expression of the Biosynthetic Gene Cluster Encoding the Antibiotic and Anticancer Agent Marinomycin”. Biomolecules, January 16, 2024
“Terpenoid balance in Aspergillus nidulans unveiled byheterologous squalene synthase expression“. ScienceAdvances, February 21, 2024

These papers represent the culmination of relentless dedication, pioneering spirit, and collaborative efforts within our research community. We extend our heartfelt gratitude to all contributors and eagerly anticipate the transformative impact of these discoveries on science and society.

Stay tuned for more exciting developments from IG scientists as we continue to push the boundaries of life sciences exploration.

On November 30 and Dec 1, 2023, Intact Genomics (IG) had the pleasure of hosting high school students from St. Louis County Parkway schools who participate in Spark and Center for Advanced Professional Studies (CAPS) programs.

Jennifer Gormley, Director of Business Development introduced our innovative products and services used by many scientists around the world, Dr. David Brent Halling, Director of Product Development at Intact Genomics, showed students how cutting-edge technology is developed at IG, and Dr. Chengcang Charles Wu, CEO & Co-founder of Intact Genomics, told a story about how he became a world-renowned scientist and dedicated entrepreneur from being a country boy born to a poor family and illiterate parents in a village of Anhui, China.

These bright students asked terrific questions showing they are eager to learn and participate in life sciences. Student Maura Korte said: “I learned a lot about proteins and how important they are in biotechnology. I feel like you usually only hear about DNA in biotechnology so it was fascinating to see that the field is so much bigger than that!” Hayden Steinkuehler said: “It was a very cool experience in seeing what we might want to do in the future.”

Spark! provides high school students with dynamic, immersion-based student learning experiences to ensure students can understand and respond to an ever-changing world. Center for Advanced Professional Studies (CAPS) programs are nationally recognized, innovative high school programs. CAPS is an example of how business, community and public education can partner to produce personalized learning experiences that educate the workforce of tomorrow, especially in high-skill, high-demand jobs. Intact Genomics is proud to do our part in inspiring talented individuals towards careers in STEM to improve the world.